Haemonetics Corporation (HAE): Price and Financial Metrics


Haemonetics Corporation (HAE)

Today's Latest Price: $118.29 USD

1.17 (-0.98%)

Updated Feb 21 6:30pm

Add HAE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

HAE Stock Summary

  • HAE's current price/earnings ratio is 86.06, which is higher than 91.9% of US stocks with positive earnings.
  • The price/operating cash flow metric for Haemonetics Corp is higher than 93.96% of stocks in our set with a positive cash flow.
  • Over the past twelve months, HAE has reported earnings growth of 89.92%, putting it ahead of 88.18% of US stocks in our set.
  • Stocks that are quantitatively similar to HAE, based on their financial statements, market capitalization, and price volatility, are NUVA, TNC, ELY, TNET, and TZOO.
  • Visit HAE's SEC page to see the company's official filings. To visit the company's web site, go to www.haemonetics.com.
HAE Daily Price Range
HAE 52-Week Price Range

HAE Stock Price Chart More Charts


HAE Price/Volume Stats

Current price $118.29 52-week high $140.36
Prev. close $119.46 52-week low $80.24
Day low $117.87 Volume 330,900
Day high $119.59 Avg. volume 501,169
50-day MA $115.99 Dividend yield N/A
200-day MA $119.09 Market Cap 5.95B

Haemonetics Corporation (HAE) Company Bio


Haemonetics designs, manufactures, and markets blood management solutions. The Company serves in three markets, such as manufacturers of plasma-derived pharmaceuticals, blood collectors, and hospitals. The company was founded in 1971 and is based in Braintree, Massachusetts.

HAE Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$118.29$19.95 -83%

Below please find a table outlining a discounted cash flow forecast for HAE, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Haemonetics Corp ranked in the 17st percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 83.33%. As for the metrics that stood out in our discounted cash flow analysis of Haemonetics Corp, consider:

  • Interest coverage, a measure of earnings relative to interest payments, is 7.13 -- which is good for besting 61.11% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • 94% of the company's capital comes from equity, which is greater than 81.84% of stocks in our cash flow based forecasting set.
  • The business' balance sheet reveals debt to be 6% of the company's capital (with equity being the remaining amount). Approximately merely 18.12% of US stocks with free cash flow have a lower reliance on debt in their capital structure.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-84%
1%-84%
2%-83%
3%-83%
4%-83%
5%-83%

AMPH, PKI, QGEN, RMD, and ZBH can be thought of as valuation peers to HAE, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


HAE Latest News Stream


Event/Time News Detail
Loading, please wait...

HAE Latest Social Stream


Loading social stream, please wait...

View Full HAE Social Stream

HAE Price Returns

1-mo 2.32%
3-mo -0.02%
6-mo -9.11%
1-year 33.48%
3-year 210.23%
5-year 171.12%
YTD 2.95%
2019 14.84%
2018 72.26%
2017 44.48%
2016 24.69%
2015 -13.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.667 seconds.